BeOne Medicines (ONC)
BeOne Medicines on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.8M
Short interest
settlement 2026-10-15
4.9
Days to cover
-0.1 days vs prior
65.1%
Short share of volume
2026-10-28
27,633
Fails to deliver
settlement 2026-09-29
Thu 5 Nov
Next earnings
estimated date
-$123.9M
Insider flow, 90 days
0 buys, 52 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 43 settlements in the table, 43 in the chart. JSONAs of 15 October 2026, short interest in ONC is 1,792,875 shares, up 85,401 shares over the last month. Over the last 43 readings it ranged from 791,577 shares (30 June 2026) to 2,522,856 shares (28 February 2025). At the reported average volume of 368K shares a day that is 4.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/onc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,792,875 | -7.3% | 367,896 | 4.87 |
| 2026-09-30 | 1,933,092 | +13.2% | 389,451 | 4.96 |
| 2026-09-15 | 1,707,474 | +20.0% | 378,473 | 4.51 |
| 2026-08-31 | 1,422,559 | +11.5% | 341,689 | 4.16 |
| 2026-08-14 | 1,276,075 | +44.9% | 455,798 | 2.80 |
| 2026-07-31 | 880,627 | -5.0% | 372,520 | 2.36 |
| 2026-07-15 | 926,986 | +17.1% | 352,696 | 2.63 |
| 2026-06-30 | 791,577 | -12.3% | 296,408 | 2.67 |
| 2026-06-15 | 902,392 | -17.2% | 311,622 | 2.90 |
| 2026-05-29 | 1,089,330 | +4.1% | 222,577 | 4.89 |
| 2026-05-15 | 1,046,818 | -5.8% | 252,348 | 4.15 |
| 2026-04-30 | 1,110,932 | -3.7% | 189,789 | 5.85 |
| 2026-04-15 | 1,154,033 | -5.0% | 217,648 | 5.30 |
| 2026-03-31 | 1,214,628 | -19.5% | 206,328 | 5.89 |
| 2026-03-13 | 1,508,660 | +1.2% | 292,623 | 5.16 |
| 2026-02-27 | 1,491,267 | -3.8% | 261,593 | 5.70 |
| 2026-02-13 | 1,549,522 | +11.2% | 236,603 | 6.55 |
| 2026-01-30 | 1,393,491 | +2.7% | 225,287 | 6.19 |
| 2026-01-15 | 1,356,462 | -16.0% | 372,552 | 3.64 |
| 2025-12-31 | 1,615,331 | +24.1% | 233,897 | 6.91 |
| 2025-12-15 | 1,302,017 | -14.5% | 289,220 | 4.50 |
| 2025-11-28 | 1,523,163 | +14.5% | 328,988 | 4.63 |
| 2025-11-14 | 1,330,164 | -15.1% | 335,811 | 3.96 |
| 2025-10-31 | 1,566,239 | +13.8% | 184,070 | 8.51 |
| 2025-10-15 | 1,376,140 | +3.9% | 245,429 | 5.61 |
| 2025-09-30 | 1,324,289 | -15.4% | 203,132 | 6.52 |
| 2025-09-15 | 1,565,996 | +5.3% | 477,715 | 3.28 |
| 2025-08-29 | 1,487,392 | -5.5% | 238,129 | 6.25 |
| 2025-08-15 | 1,574,456 | -11.0% | 424,663 | 3.71 |
| 2025-07-31 | 1,769,390 | +9.1% | 473,950 | 3.73 |
| 2025-07-15 | 1,622,047 | -10.0% | 314,066 | 5.16 |
| 2025-06-30 | 1,802,393 | -6.3% | 357,213 | 5.05 |
| 2025-06-13 | 1,922,550 | -5.4% | 353,556 | 5.44 |
| 2025-05-30 | 2,031,401 | -0.1% | 267,600 | 7.59 |
| 2025-05-15 | 2,033,539 | -2.5% | 448,726 | 4.53 |
| 2025-04-30 | 2,084,791 | +4.6% | 436,198 | 4.78 |
| 2025-04-15 | 1,993,463 | +24.8% | 708,470 | 2.81 |
| 2025-03-31 | 1,597,557 | -2.9% | 411,823 | 3.88 |
| 2025-03-14 | 1,644,651 | -34.8% | 588,472 | 2.79 |
| 2025-02-28 | 2,522,856 | +70.6% | 711,970 | 3.54 |
| 2025-02-14 | 1,479,000 | +5.2% | 336,983 | 4.39 |
| 2025-01-31 | 1,405,760 | +11.6% | 319,897 | 4.39 |
| 2025-01-15 | 1,259,698 | -4.0% | 324,733 | 3.88 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of ONC volume is 65.1%, down 12.0 points over the last five sessions. Over the last 30 readings it ranged from 49.1% (30 September 2026) to 82.8% (23 September 2026). The latest reading is 2.1 points below the 30-session average of 67.2%, on 126K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 82K | 126K | 65.1% | 0 |
| 2026-10-27 | 110K | 171K | 64.6% | 8 |
| 2026-10-26 | 91K | 138K | 66.0% | 80 |
| 2026-10-23 | 75K | 118K | 63.8% | 192 |
| 2026-10-22 | 95K | 129K | 73.5% | 425 |
| 2026-10-21 | 169K | 219K | 77.1% | 8,731 |
| 2026-10-20 | 95K | 150K | 63.1% | 385 |
| 2026-10-19 | 65K | 98K | 66.6% | 0 |
| 2026-10-16 | 95K | 137K | 69.5% | 1,617 |
| 2026-10-15 | 170K | 257K | 66.0% | 1,002 |
| 2026-10-14 | 67K | 94K | 70.8% | 0 |
| 2026-10-13 | 69K | 110K | 62.9% | 0 |
| 2026-10-12 | 51K | 77K | 66.9% | 0 |
| 2026-10-09 | 54K | 71K | 75.7% | 183 |
| 2026-10-08 | 105K | 153K | 68.2% | 5 |
| 2026-10-07 | 36K | 53K | 67.7% | 15 |
| 2026-10-06 | 51K | 93K | 55.3% | 0 |
| 2026-10-05 | 44K | 83K | 52.8% | 0 |
| 2026-10-02 | 138K | 174K | 79.3% | 5 |
| 2026-10-01 | 49K | 94K | 51.9% | 0 |
| 2026-09-30 | 48K | 98K | 49.1% | 40 |
| 2026-09-29 | 125K | 158K | 79.0% | 3,863 |
| 2026-09-28 | 100K | 132K | 75.7% | 0 |
| 2026-09-25 | 94K | 154K | 61.0% | 0 |
| 2026-09-24 | 122K | 164K | 74.4% | 5 |
| 2026-09-23 | 211K | 255K | 82.8% | 20 |
| 2026-09-22 | 62K | 99K | 61.9% | 100 |
| 2026-09-21 | 84K | 119K | 70.8% | 77 |
| 2026-09-18 | 88K | 136K | 65.1% | 0 |
| 2026-09-17 | 80K | 115K | 69.1% | 707 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 29 September 2026, the fails-to-deliver balance in ONC is 27,633 shares, up 27,610 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (19 August 2026) to 27,633 shares (29 September 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-29 | 27,633 | $367.00 | $10.1M |
| 2026-09-24 | 23 | $365.00 | $8K |
| 2026-09-21 | 100 | $350.84 | $35K |
| 2026-09-09 | 7 | $351.48 | $2K |
| 2026-08-24 | 106 | $374.47 | $40K |
| 2026-08-19 | 1 | $369.15 | $369 |
| 2026-08-18 | 1,091 | $362.51 | $395K |
| 2026-08-12 | 6 | $359.27 | $2K |
| 2026-08-11 | 1,541 | $359.00 | $553K |
| 2026-08-10 | 1,092 | $348.27 | $380K |
| 2026-07-27 | 911 | $325.90 | $297K |
| 2026-07-20 | 380 | $312.02 | $119K |
| 2026-07-14 | 440 | $303.96 | $134K |
| 2026-07-13 | 477 | $298.70 | $142K |
| 2026-07-10 | 24 | $302.83 | $7K |
| 2026-07-09 | 2 | $301.88 | $604 |
| 2026-07-08 | 890 | $308.96 | $275K |
| 2026-07-07 | 81 | $309.46 | $25K |
| 2026-07-02 | 3 | $290.74 | $872 |
| 2026-07-01 | 4,703 | $284.97 | $1.3M |
| 2026-06-30 | 421 | $289.99 | $122K |
| 2026-06-29 | 244 | $279.89 | $68K |
| 2026-06-11 | 18 | $263.61 | $5K |
| 2026-05-28 | 585 | $300.01 | $176K |
| 2026-05-21 | 1,274 | $308.74 | $393K |
| 2026-05-14 | 665 | $316.55 | $211K |
| 2026-05-05 | 304 | $297.14 | $90K |
| 2026-05-04 | 304 | $293.86 | $89K |
| 2026-04-20 | 99 | $323.87 | $32K |
| 2026-04-16 | 10,000 | $319.94 | $3.2M |
Insider trades
SEC Form 4, newest first. JSONInsiders at ONC reported 52 open-market sells worth $123.9M in the last 90 days and no open-market buys. Latest filing: Wang Xiaodong (Director, Chair, Scientific Advisory Brd) on 2026-10-13.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 1K | $353.24 | $445K | 0 |
| 2026-10-13 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 7K | $352.57 | $2.3M | 1K |
| 2026-10-13 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 6K | $351.40 | $2.0M | 8K |
| 2026-10-13 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 10K | $350.47 | $3.6M | 13K |
| 2026-10-13 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 7K | $349.56 | $2.5M | 24K |
| 2026-10-13 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Exercise or conversion | 31K | $36.90 | $1.1M | 31K |
| 2026-09-30 | Lee Chan Henry | SVP, General Counsel | Sell | 1K | $375.00 | $418K | 0 |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 738 | $367.23 | $271K | 0 |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 15K | $366.58 | $5.3M | 738 |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 2K | $365.85 | $749K | 15K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 3K | $364.07 | $1.2M | 17K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 3K | $363.10 | $1.3M | 21K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 4K | $362.17 | $1.5M | 24K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 2K | $361.05 | $809K | 28K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 40 | $359.16 | $14K | 31K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 120 | $358.71 | $43K | 31K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 160 | $356.97 | $57K | 31K |
| 2026-09-28 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Exercise or conversion | 31K | $36.90 | $1.1M | 31K |
| 2026-09-14 | BAKER BROS. ADVISORS LP | Director | Exercise or conversion | 31K | $36.83 | $1.1M | 8.1M |
| 2026-09-14 | BAKER BROS. ADVISORS LP | Director | Exercise or conversion | 31K | $36.83 | $1.1M | 761K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 6K | $351.25 | $2.2M | 0 |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 7K | $350.27 | $2.3M | 6K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 11K | $349.28 | $3.7M | 13K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 7K | $348.31 | $2.6M | 24K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Exercise or conversion | 31K | $36.90 | $1.1M | 31K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 2K | $348.01 | $599K | 0 |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 2K | $347.39 | $527K | 2K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 3K | $346.16 | $983K | 3K |
| 2026-09-08 | Wang Xiaodong | Director, Chair, Scientific Advisory Brd | Sell | 1K | $345.38 | $408K | 6K |
| 2026-09-01 | Ball Titus B. | Principal Accounting Officer | Sell | 132 | $355.86 | $47K | 0 |
| 2026-08-25 | Wu Xiaobin | President and COO | Sell | 280 | $380.00 | $106K | 0 |
| 2026-08-12 | OYLER JOHN | Chief Executive Officer | Sell | 14K | $359.12 | $5.1M | 0 |
| 2026-08-12 | OYLER JOHN | Chief Executive Officer | Sell | 21K | $358.41 | $7.5M | 14K |
| 2026-08-12 | OYLER JOHN | Chief Executive Officer | Sell | 15K | $357.63 | $5.5M | 35K |
| 2026-08-12 | OYLER JOHN | Chief Executive Officer | Sell | 3K | $356.43 | $896K | 50K |
| 2026-08-12 | OYLER JOHN | Chief Executive Officer | Sell | 2K | $354.71 | $702K | 53K |
| 2026-08-11 | Lee Chan Henry | SVP, General Counsel | Sell | 3K | $360.00 | $960K | 0 |
| 2026-08-11 | Lee Chan Henry | SVP, General Counsel | Exercise or conversion | 796 | $159.03 | $127K | 3K |
| 2026-08-11 | Lee Chan Henry | SVP, General Counsel | Exercise or conversion | 1K | $213.32 | $226K | 2K |
| 2026-08-11 | Lee Chan Henry | SVP, General Counsel | Exercise or conversion | 812 | $194.47 | $158K | 812 |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 4 | $367.00 | $1K | 55K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 1K | $366.31 | $440K | 55K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 3K | $365.26 | $1.2M | 56K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 5K | $364.31 | $1.9M | 59K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 13K | $363.45 | $4.9M | 64K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 12K | $362.34 | $4.2M | 78K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 15K | $361.47 | $5.3M | 89K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 8K | $360.33 | $2.9M | 104K |
| 2026-08-11 | OYLER JOHN | Chief Executive Officer | Sell | 14K | $359.32 | $4.9M | 112K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 4K | $360.63 | $1.3M | 126K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 21K | $359.50 | $7.6M | 129K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 45K | $358.70 | $16.2M | 151K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 16K | $357.67 | $5.7M | 196K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 12K | $356.62 | $4.4M | 212K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 3K | $355.66 | $1.2M | 224K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 7K | $354.78 | $2.4M | 228K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 4K | $353.32 | $1.3M | 234K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 3K | $351.80 | $990K | 238K |
| 2026-08-10 | OYLER JOHN | Chief Executive Officer | Sell | 67 | $350.00 | $23K | 241K |
| 2026-08-03 | Rosenberg Aaron | Chief Financial Officer | Sell | 1K | $312.71 | $362K | 0 |
| 2026-07-30 | Lee Chan Henry | SVP, General Counsel | Sell | 1K | $323.69 | $338K | 0 |
| 2026-07-22 | Lee Chan Henry | SVP, General Counsel | Sell | 2K | $325.00 | $542K | 0 |
| 2026-07-22 | Lee Chan Henry | SVP, General Counsel | Exercise or conversion | 490 | $159.03 | $78K | 2K |
| 2026-07-22 | Lee Chan Henry | SVP, General Counsel | Exercise or conversion | 665 | $213.32 | $142K | 1K |
| 2026-07-22 | Lee Chan Henry | SVP, General Counsel | Exercise or conversion | 514 | $194.47 | $100K | 514 |
| 2026-07-21 | OYLER JOHN | Chief Executive Officer | Sell | 2K | $320.06 | $749K | 0 |
| 2026-07-21 | OYLER JOHN | Chief Executive Officer | Sell | 16K | $319.29 | $5.0M | 2K |
| 2026-07-21 | OYLER JOHN | Chief Executive Officer | Sell | 8K | $318.41 | $2.5M | 18K |
| 2026-07-21 | OYLER JOHN | Chief Executive Officer | Sell | 20K | $316.91 | $6.3M | 26K |
| 2026-07-21 | OYLER JOHN | Chief Executive Officer | Sell | 15K | $316.26 | $4.9M | 46K |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 280 | $318.30 | $89K | 0 |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 523 | $316.14 | $165K | 280 |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 2K | $315.26 | $477K | 803 |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 2K | $313.91 | $581K | 2K |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 14K | $312.96 | $4.5M | 4K |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 15K | $312.29 | $4.8M | 18K |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Exercise or conversion | 34K | $119.96 | $4.1M | 34K |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 3K | $311.80 | $906K | 0 |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 6K | $310.75 | $1.9M | 3K |
| 2026-07-20 | OYLER JOHN | Chief Executive Officer | Sell | 5K | $310.08 | $1.6M | 9K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 51 | $315.06 | $16K | 0 |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 740 | $314.32 | $233K | 51 |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 15K | $313.19 | $4.7M | 791 |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 36K | $312.17 | $11.2M | 16K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 6K | $311.42 | $1.7M | 52K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 5K | $310.37 | $1.5M | 57K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 680 | $309.05 | $210K | 62K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 597 | $306.96 | $183K | 63K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Sell | 1K | $305.20 | $439K | 63K |
| 2026-07-17 | OYLER JOHN | Chief Executive Officer | Exercise or conversion | 65K | $119.96 | $7.8M | 65K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 520 | $323.59 | $168K | 0 |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 2K | $322.71 | $503K | 520 |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 13K | $321.61 | $4.2M | 2K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 21K | $321.00 | $6.6M | 15K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 15K | $319.99 | $4.8M | 36K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 6K | $318.55 | $2.0M | 51K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 43K | $317.79 | $13.6M | 57K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 32K | $316.82 | $10.2M | 100K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 20K | $316.00 | $6.2M | 132K |
| 2026-07-16 | OYLER JOHN | Chief Executive Officer | Sell | 10K | $314.73 | $3.0M | 152K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON48 Form 144 notices on file for ONC worth $420.4M at the prices reported; 8 in the last 90 days worth $138.8M. Latest: CHAN LEE filed on 2026-09-30 to sell 1,115 shares ($407K) from 2026-09-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-30 | CHAN LEEOfficer | 1K | $407K | 0.002% | 2026-09-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-08 | XIAODONG WANGDirector, Chair, Scientific Advisory Brd | 131K | $47.1M | 0.227% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-01 | TITUS BENJAMIN BALLOfficer | 132 | $47K | 0.000% | 2026-09-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | XIAOBIN WUOfficer | 15K | $5.6M | 0.026% | 2026-08-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | CORAZON D. SANDERSFormer Director | 2K | $789K | 0.004% | 2026-08-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-11 | CHAN LEEOfficer | 2K | $719K | 0.003% | 2026-08-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-10 | JOHN V OYLERDirector, Officer | 241K | $83.9M | 0.416% | 2026-08-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | AARON ROSENBERGOfficer | 1K | $362K | 0.002% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-30 | CHAN LEEOfficer | 1K | $338K | 0.002% | 2026-07-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-22 | CHAN LEEOfficer | 2K | $638K | 0.004% | 2026-07-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-14 | JOHN V OYLERDirector, Officer | 514K | $156.1M | 0.936% | 2026-07-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-10 | JOHN V OYLERDirector, Officer | 150K | $45.4M | 0.273% | 2026-07-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-10 | PAN-OYLER FOUNDATIONDirector, Officer | 50K | $15.0M | 0.090% | 2026-07-10 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | LAI WANGOfficer | 1K | $296K | 0.002% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | XIAOBIN WUOfficer | 1K | $357K | 0.002% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | JOHN OYLEROfficer, Director | 3K | $934K | 0.006% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-16 | CHAN LEEOfficer | 590 | $157K | 0.001% | 2026-06-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-16 | LAI WANGOfficer | 1K | $310K | 0.002% | 2026-06-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-16 | XIAOBIN WUOfficer | 1K | $362K | 0.002% | 2026-06-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-16 | JOHN OYLEROfficer, Director | 4K | $981K | 0.007% | 2026-06-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | CORAZON D. SANDERSDirector | 945 | $251K | 0.002% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | XIAOBIN WUOfficer | 626 | $164K | 0.001% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | LAI WANGOfficer | 756 | $198K | 0.001% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | AARON ROSENBERGOfficer | 631 | $163K | 0.001% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | CHAN LEEOfficer | 428 | $110K | 0.001% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | JOHN OYLEROfficer, Director | 2K | $501K | 0.004% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-11 | TITUS BENJAMIN BALLOfficer | 169 | $43K | 0.000% | 2026-06-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | CHAN LEEOfficer | 871 | $236K | 0.002% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | LAI WANGOfficer | 1K | $368K | 0.002% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | XIAOBIN WUOfficer | 1K | $400K | 0.003% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | JOHN OYLEROfficer, Director | 5K | $1.3M | 0.009% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-08 | TITUS BENJAMIN BALLOfficer | 136 | $37K | 0.000% | 2026-06-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | QINGQING YIDirector | 235 | $66K | 0.000% | 2026-06-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-22 | MICHAEL GOLLERDirector | 211 | $65K | 0.000% | 2026-05-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-22 | RANJEEV KRISHANADirector | 212 | $66K | 0.000% | 2026-05-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-22 | ALESSANDRO RIVADirector | 212 | $66K | 0.000% | 2026-05-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-22 | MARGARET DUGANDirector | 212 | $66K | 0.000% | 2026-05-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-22 | CORAZON D. SANDERSDirector | 212 | $66K | 0.000% | 2026-05-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-13 | CHAN LEEOfficer | 1K | $418K | 0.002% | 2026-05-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-04 | CHAN LEEOfficer | 5K | $1.6M | 0.009% | 2026-02-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | JOHN V OYLERDirector, Officer | 100K | $31.9M | 0.185% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-26 | CORAZON D. SANDERSDirector | 3K | $896K | 0.005% | 2025-11-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | XIAOBIN WUOfficer | 4K | $1.5M | 0.004% | 2025-11-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-13 | XIAOBIN WUOfficer | 6K | $2.3M | 0.005% | 2025-11-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-12 | XIAOBIN WUOfficer | 10K | $3.6M | 0.009% | 2025-11-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-08 | CHAN LEEOfficer | 14K | $4.7M | 0.025% | 2025-10-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-16 | PAN-OYLER FOUNDATIONDirector, Officer | 1K | $400K | 0.002% | 2025-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-16 | JOHN V OYLERDirector, Officer | 28K | $9.2M | 0.051% | 2025-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of ONC in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Felix J. Baker at 7.8% of the class (115,912,814 shares), filed 2026-09-16 for an event on 2026-09-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-16 | 13D/Ano. 14 | Felix J. Bakerindividual, parent holding company | 115.9M | 7.8% | 2026-09-14 |
| 2026-09-16 | 13D/Ano. 14 | Julian C. Bakerindividual, parent holding company | 115.9M | 7.8% | 2026-09-14 |
| 2026-09-16 | 13D/Ano. 14 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 115.5M | 7.8% | 2026-09-14 |
| 2026-09-16 | 13D/Ano. 14 | Baker Bros. Advisors LPinvestment adviser, partnership | 115.5M | 7.8% | 2026-09-14 |
| 2026-09-16 | 13D/Ano. 14 | FBB3 LLCother entity | 145K | 0.0% | 2026-09-14 |
| 2026-05-14 | 13G/Ano. 6 | Capital International Investorsinvestment adviser | 65.2M | 4.2% | 2026-03-31 |
13F holders
Tracked managers holding ONC at their latest 13F. JSON4 of the 30 tracked managers held ONC at their latest 13F, $671.8M in total at quarter-end prices. Citadel Advisors is the largest at $406.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 1.4M | $406.2M | 0.05% | +393K |
| Millennium Management | 2026-06-30 | 543K | $154.8M | 0.06% | +338K |
| Two Sigma Investments | 2026-06-30 | 287K | $81.7M | 0.06% | +253K |
| Renaissance Technologies | 2026-06-30 | 102K | $29.1M | 0.04% | +37K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) BeOne Medicines reported revenue of $1.71B, up 29.6% from the same quarter a year earlier, and net income of $237.0M (0.16 diluted EPS). In FY 2025 it generated $1.13B of operating cash flow. As of 2026-06-30, cash was $5.10B against $788.7M of debt.
- Cash
- $5.10B
- Debt
- $788.7M
- Equity
- $5.17B
- Total assets
- $9.18B
- Shares outstanding
- 1,478,124,405
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $1.71B | $237.0M | 13.9% | 0.16 |
| Q1 FY 2026 | 2026-03-31 | $1.51B | $227.4M | 15.0% | 0.15 |
| Q4 FY 2025derived | 2025-12-31 | $1.50B | $66.5M | 4.4% | n/a |
| Q3 FY 2025 | 2025-09-30 | $1.41B | $124.8M | 8.8% | 0.08 |
| Q2 FY 2025 | 2025-06-30 | $1.32B | $94.3M | 7.2% | 0.06 |
| Q1 FY 2025 | 2025-03-31 | $1.12B | $1.3M | 0.1% | 0.00 |
| Q4 FY 2024derived | 2024-12-31 | $1.13B | -$151.9M | -13.5% | n/a |
| Q3 FY 2024 | 2024-09-30 | $1.00B | -$121.3M | -12.1% | -0.09 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $5.34B | $286.9M | $1.13B | $185.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $3.81B | -$644.8M | -$140.6M | $492.7M | n/a | n/a |
| FY 2023 | 2023-12-31 | $2.46B | -$881.7M | -$1.16B | $561.9M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.42B | -$2.00B | -$1.50B | $325.4M | n/a | n/a |
| FY 2021 | 2021-12-31 | $1.18B | -$1.46B | -$1.30B | $262.9M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
BeOne Medicines in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows BeOne Medicines (ONC), SEC CIK 1651308, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-29.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-16.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-26.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-13.JSON and CSV
- Company record
- EDGAR filing index for CIK 1651308Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ONC is sold short?
1,792,875 shares were held short at the 2026-10-15 settlement, 4.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ONC's daily short volume?
On 2026-10-28, 81,794 of the 125,691 ONC shares reported to FINRA were sold short, 65.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ONC have fails to deliver?
The SEC's latest file shows 27,633 ONC shares failed to deliver at settlement 2026-09-29. Fails are reported per settlement date and published twice a month with a lag.
Are ONC insiders buying or selling?
Insiders at ONC reported 52 open-market sells worth $123.9M in the last 90 days and no open-market buys. Latest filing: Wang Xiaodong (Director, Chair, Scientific Advisory Brd) on 2026-10-13.
Have ONC insiders filed to sell?
48 Form 144 notices on file for ONC worth $420.4M at the prices reported; 8 in the last 90 days worth $138.8M. Latest: CHAN LEE filed on 2026-09-30 to sell 1,115 shares ($407K) from 2026-09-30.
Who owns 5% or more of ONC?
4 holders report 5% or more of ONC in their latest filing, all on Schedule 13D (active intent). The largest reported stake is Felix J. Baker at 7.8% of the class (115,912,814 shares), filed 2026-09-16 for an event on 2026-09-14.
What did ONC report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) BeOne Medicines reported revenue of $1.71B, up 29.6% from the same quarter a year earlier, and net income of $237.0M (0.16 diluted EPS). In FY 2025 it generated $1.13B of operating cash flow. As of 2026-06-30, cash was $5.10B against $788.7M of debt.
Which tracked 13F managers own ONC?
4 of the 30 tracked 13F managers held ONC shares at their latest filing, $671.8M in all. The largest: Ken Griffin's Citadel Advisors (1.4M shares, $406.2M), Izzy Englander's Millennium Management (543K shares, $154.8M), Two Sigma Investments (287K shares, $81.7M), Renaissance Technologies (102K shares, $29.1M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.